Literature DB >> 9139490

Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population.

A D Bentsi-Enchill1, S A Halperin, J Scott, K MacIsaac, P Duclos.   

Abstract

Pertussis has re-emerged as a public health problem in Canada in recent years, emphasizing concerns about the effectiveness of the currently licensed whole-cell vaccine. Following a 1994 outbreak in Nova Scotia, we conducted a case-control study of 483 children aged < 10 years to assess vaccine effectiveness. Ninety-three percent of children aged 6 months and above had received three or more doses of vaccine, however, only 78% had received age-appropriate immunization. Among children aged 4 years and more, vaccine effectiveness against laboratory-confirmed pertussis was 57% (95% CI, 23-77%) for age-appropriate immunization (five doses) vs partial or no immunization. Vaccine effectiveness increased with increasing number of doses from 25% (95% CI, -58-65%) for three or more doses to 55% (95% CI, -15-83%) for five doses, compared with 0-2 doses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9139490     DOI: 10.1016/s0264-410x(96)00176-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Economic evaluation of a new acellular vaccine for pertussis in Canada.

Authors:  M Iskedjian; T R Einarson; B J O'Brien; J G De Serres; R Gold; I M Gemmill; N Milkovich; A Rosner
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada.

Authors:  Raymond S W Tsang; Allan K H Lau; Michelle L Sill; Scott A Halperin; Paul Van Caeseele; Frances Jamieson; Irene E Martin
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

3.  Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.

Authors:  Michael Iskedjian; John H Walker; Gaston De Serres; Thomas R Einarson
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Has the change to acellular pertussis vaccine improved or worsened pertussis control?

Authors:  Scott A Halperin; Gaston De Serres
Journal:  CMAJ       Date:  2006-11-07       Impact factor: 8.262

Review 5.  Changing epidemiology and emerging risk groups for pertussis.

Authors:  Eleni Galanis; Arlene S King; Paul Varughese; Scott Alan Halperin
Journal:  CMAJ       Date:  2006-02-14       Impact factor: 8.262

6.  The role of the acellular pertussis vaccine and the demise of 'Pertussis Pete'.

Authors:  J M Conly; B L Johnston
Journal:  Can J Infect Dis       Date:  2001-01

Review 7.  Prevention of pertussis: An unresolved problem.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2018-07-24       Impact factor: 3.452

8.  The return of the 100-day cough: resurgence of pertussis in the 1990s.

Authors:  T W Tam; A Bentsi-Enchill
Journal:  CMAJ       Date:  1998-09-22       Impact factor: 8.262

Review 9.  Licensed pertussis vaccines in the United States. History and current state.

Authors:  Nicola P Klein
Journal:  Hum Vaccin Immunother       Date:  2014-11-06       Impact factor: 3.452

10.  Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data.

Authors:  H E de Melker; J F Schellekens; S E Neppelenbroek; F R Mooi; H C Rümke; M A Conyn-van Spaendonck
Journal:  Emerg Infect Dis       Date:  2000 Jul-Aug       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.